noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

Amylyx Pharmaceuticals Inc.

Results Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc.

– Enrollment exceeding expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash and investments on

-3d
Amylyx Pharmaceuticals Inc.

WATERTOWN, Mass. , March 17, 2025 (GLOBE NEWSWIRE) EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non statutory stock

-3d
Amylyx Pharmaceuticals Inc.

WATERTOWN, Mass. , March 27, 2025 (GLOBE NEWSWIRE) EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S.

-3d
Amylyx Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

-3d
Amylyx Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

-3d
Amylyx Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

-3d
Amylyx Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

-3d
Amylyx Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

-3d
Amylyx Pharmaceuticals Inc.

Notice of Effectiveness (Form EFFECT)

3/27
Amylyx Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

3/24